Research Analysts Issue Forecasts for BMRN FY2026 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for BioMarin Pharmaceutical in a report released on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer forecasts that the biotechnology company will earn $4.29 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $90.00 price objective on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

Several other equities research analysts have also recently issued reports on BMRN. UBS Group lifted their price objective on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Oppenheimer raised BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price target on the stock in a research note on Monday, February 24th. Citigroup reduced their price objective on BioMarin Pharmaceutical from $82.00 to $78.00 and set a “neutral” rating for the company in a research note on Friday, May 2nd. Scotiabank raised their price objective on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a “sector perform” rating in a report on Thursday, February 20th. Finally, Bank of America upped their target price on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $93.45.

BioMarin Pharmaceutical Stock Up 0.4%

BMRN stock opened at $56.88 on Tuesday. BioMarin Pharmaceutical has a 52 week low of $52.93 and a 52 week high of $94.85. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The firm has a 50-day simple moving average of $59.40 and a 200-day simple moving average of $64.21. The stock has a market capitalization of $10.91 billion, a P/E ratio of 25.85, a P/E/G ratio of 0.61 and a beta of 0.19.

Insider Transactions at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,786 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total value of $105,927.66. Following the sale, the chief accounting officer now directly owns 14,173 shares of the company’s stock, valued at approximately $840,600.63. The trade was a 11.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 3,354 shares of company stock worth $216,269 in the last 90 days. Insiders own 0.85% of the company’s stock.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds have recently made changes to their positions in the business. Bleakley Financial Group LLC purchased a new stake in BioMarin Pharmaceutical during the 4th quarter worth approximately $330,000. Sumitomo Mitsui Trust Group Inc. boosted its holdings in BioMarin Pharmaceutical by 3.1% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 470,043 shares of the biotechnology company’s stock valued at $30,896,000 after purchasing an additional 13,946 shares during the period. Empowered Funds LLC purchased a new position in BioMarin Pharmaceutical in the fourth quarter valued at $257,000. Entropy Technologies LP acquired a new position in BioMarin Pharmaceutical during the 4th quarter worth $500,000. Finally, WCM Investment Management LLC increased its holdings in BioMarin Pharmaceutical by 3.5% during the 4th quarter. WCM Investment Management LLC now owns 17,540 shares of the biotechnology company’s stock worth $1,148,000 after purchasing an additional 595 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.